Related Experiment Video
Updated: Feb 9, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.8K
A new era in headache treatment
Michail Vikelis1,2, Konstantinos C Spingos3, Alan M Rapoport4
1Glyfada Headache Clinic, No. 8 Lazaraki Str., 16675, Glyfada, Greece. mvikelis@headaches.gr.
Summary
New treatments for primary headache disorders like migraine are emerging. Advances include calcitonin gene-related peptide (CGRP) blockers, offering new hope for effective preventive therapy and improved patient adherence.
Area of Science:
- Neurology
- Pharmacology
Background:
- Primary headache disorders, including migraine and cluster headache, are prevalent and significantly impact quality of life.
- Current oral preventive therapies often suffer from poor patient adherence and persistence.
- There is a critical need for novel and effective treatment strategies.
Purpose of the Study:
- To review recent advances in the acute and preventive treatment of migraine and cluster headache.
- To highlight the potential of novel therapeutic targets and delivery systems.
- To discuss the anticipated impact of new treatments on patient management.
Main Methods:
- Literature review of recent clinical trials and research publications.
- Analysis of emerging therapeutic classes, including CGRP inhibitors.
- Discussion of innovative delivery systems and devices.
Main Results:
- Calcitonin gene-related peptide (CGRP) targeted therapies are poised to revolutionize migraine prevention.
- Non-triptan serotonin receptor agonists offer alternative acute treatment options.
- Newer delivery systems and devices show promise for improved efficacy and patient experience.
Conclusions:
- The landscape of migraine and cluster headache treatment is rapidly evolving.
- CGRP inhibitors represent a significant breakthrough in preventive care.
- Future research and development in devices and drug delivery will further enhance patient outcomes.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:24Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
01:22Alzheimer's Disease: Treatment
968
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
968
01:26Anticholinesterase Agents: Poisoning and Treatment
1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
01:28Angle Closure Glaucoma: Treatment
1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K